Triptorelin (Trelstar / Decapeptyl)

1. Overview

Triptorelin (D-Trp6-LHRH) is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) classified as a GnRH superagonist [1][13][16]. Developed in the late 1970s by Andrew Schally's group, triptorelin incorporates a single amino acid substitution -- D-tryptophan replacing glycine at position 6 -- which confers approximately 100-fold greater potency than native GnRH and dramatically increases metabolic stability [13][14][16].

The amino acid sequence is pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2, with a molecular weight of 1311.5 Da [15]. Unlike leuprolide, which has both a D-Leu6 substitution and a C-terminal ethylamide modification (des-Gly10), triptorelin retains the native C-terminal Gly10-NH2, with the D-Trp6 substitution alone providing sufficient enzymatic resistance and receptor affinity enhancement [1][13]. The bulky indole ring of D-tryptophan at position 6 both prevents endopeptidase cleavage at the Gly6-Leu7 bond and enhances receptor binding by stabilizing the beta-turn conformation favored by the GnRH receptor [11][13].

Triptorelin is marketed as Trelstar (triptorelin pamoate) in the United States, where it was FDA-approved in 2000 for advanced prostate cancer, and as Decapeptyl in Europe and much of the world, where it has broader approved indications including endometriosis, uterine fibroids, central precocious puberty, and assisted reproduction [1][15]. In European practice, triptorelin is the most commonly prescribed GnRH agonist, while leuprolide dominates the US market [5][17].

Type

GnRH superagonist (decapeptide)

Molecular Weight

1311.5 Da (free base)

Molecular Formula

C₆₄H₂H₈₂N₁₈O₁₃

Sequence

pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2

Modification vs Native GnRH

D-Trp6 substitution

Potency vs Native GnRH

~100-fold more potent

Half-life

~3-5 hours (free peptide); formulation-dependent depot release

Routes

Intramuscular (depot formulations)

FDA Status

Approved (Trelstar, 2000 for advanced prostate cancer)

Key Depot Formulations

3.75 mg (1-month), 11.25 mg (3-month), 22.5 mg (6-month)

2. Mechanism of Action

2.1 The Agonist Paradox

Like all GnRH superagonists, triptorelin's therapeutic mechanism exploits the fundamental difference between pulsatile and continuous GnRH signaling, first demonstrated by Belchetz, Knobil, and colleagues in 1978 [12]:

Phase 1 -- Initial Stimulation (Days 1-7). Triptorelin binds GnRH type I receptors on anterior pituitary gonadotrophs with high affinity, activating Gq/11 signaling, phospholipase C-beta, and calcium-dependent exocytosis of stored LH and FSH. This produces a transient "flare" of gonadotropins with consequent rises in testosterone (men) or estradiol (women) [11][13][14].

Phase 2 -- Receptor Desensitization (Days 7-21). Continuous receptor occupancy by triptorelin triggers [11][13]:

• GnRH receptor internalization and lysosomal degradation
• Downregulation of GnRH-R mRNA expression
• Uncoupling from Gq/11 signaling
• Depletion of intracellular calcium stores and PKC isoforms
• Suppression of LH-beta and FSH-beta subunit transcription

Phase 3 -- Sustained Suppression (Week 3 onward). By 2-4 weeks, serum testosterone falls to castrate levels (at or below 50 ng/dL, often at or below 20 ng/dL) in men, and estradiol falls to postmenopausal levels (at or below 20 pg/mL) in women. This suppression is maintained throughout treatment and is reversible upon discontinuation [1][14][15].

3. Pharmacokinetics

3.1 Depot Release Kinetics by Formulation

The pharmacokinetics of triptorelin are governed by its PLGA (poly-lactic-co-glycolic acid) microsphere depot formulation, which controls drug release over 1, 3, or 6 months [4][15][17].

1-Month Depot (3.75 mg IM). An initial burst release occurs within the first 24-48 hours post-injection, producing a peak plasma concentration (Cmax) of approximately 28-40 ng/mL within 1-3 hours. Levels then decline over 2-3 days to a trough of approximately 0.1-0.2 ng/mL, maintained as a sustained-release plateau for 28 days. The biphasic release pattern -- initial burst followed by steady erosion-controlled release -- ensures continuous receptor exposure throughout the dosing interval [15].

3-Month Depot (11.25 mg IM). The Cmax is approximately 38-47 ng/mL within the first few hours, declining to a steady-state plateau of 0.02-0.2 ng/mL that is sustained for 84 days. The larger PLGA microspheres used in the 3-month formulation degrade more slowly, extending the release window. Trough levels are slightly lower than the monthly depot but remain above the minimum effective concentration for castration maintenance [4][15].

6-Month Depot (22.5 mg IM). Peak levels reach approximately 50-60 ng/mL in the initial burst phase. Steady-state plateau concentrations of 0.01-0.15 ng/mL are sustained for 168 days. In the pivotal trial, testosterone breakthrough (transient rises above 50 ng/dL) occurred in fewer than 3% of patients, confirming adequate sustained release over the full 6-month dosing interval [4].

3.2 Distribution and Metabolism

Free triptorelin has a terminal elimination half-life of 3-5 hours. The volume of distribution is approximately 30-33 L. There is no evidence of significant plasma protein binding beyond the IGFBP-type carrier interactions seen with other peptides. Triptorelin is metabolized primarily by tissue peptidases through enzymatic hydrolysis of the peptide backbone. The D-Trp6 modification substantially slows but does not eliminate proteolytic degradation [15]. No hepatic CYP450-mediated metabolism has been identified, and no drug-drug interactions have been reported [15].

3.3 Elimination

Renal clearance accounts for the majority of systemic elimination, with approximately 42% of the administered free peptide dose recovered in urine (based on IV pharmacokinetic studies). No dose adjustment is required for mild-to-moderate renal or hepatic impairment, though no formal studies have been conducted in severe renal failure [15].

3.4 Testosterone Suppression Kinetics

The pharmacodynamic response follows a predictable temporal pattern across all formulations:

• Days 1-3: Testosterone flare, with levels rising to 150-200% of baseline (men)
• Days 7-14: Progressive testosterone decline as pituitary desensitization takes effect
• Days 21-29: Castrate levels (at or below 50 ng/dL) achieved in 95-97% of patients
• Maintenance: Sustained castration throughout the dosing interval in 93-97% depending on formulation

Recovery of testosterone to baseline occurs within 2-6 months of treatment discontinuation, with mean recovery time of approximately 3 months [1][15].

4. Dose-Response Relationships

4.1 Testosterone Suppression Across Depot Formulations

Clinical evidence demonstrates a therapeutic plateau for testosterone suppression across the three depot formulations, with no meaningful dose-response relationship for efficacy above the approved doses [1][4][5]:

| Parameter | 3.75 mg Monthly | 11.25 mg 3-Monthly | 22.5 mg 6-Monthly | |-----------|----------------|--------------------|--------------------| | Castration by Day 29 | 97% | 95-96% | 96.7% | | Sustained castration | 93% (9 months) | 94-96% (12 months) | 97.4% (48 weeks) | | Testosterone breakthrough | 3-7% | 4-6% | 2-3% | | Mean nadir testosterone | 12-15 ng/dL | 10-14 ng/dL | 11-16 ng/dL | | PSA decline at 6 months | more than 90% | more than 90% | more than 90% |

The 6-month formulation demonstrates slightly lower breakthrough rates, possibly because the higher total drug load provides a more consistent sustained-release plateau [4]. All three formulations achieve testosterone levels well below the 50 ng/dL threshold, with most patients reaching levels at or below 20 ng/dL -- the more stringent modern castration standard [5].

4.2 Endometriosis Dose-Response

For endometriosis, the standard 3.75 mg monthly dose achieves estradiol suppression to postmenopausal levels (at or below 20 pg/mL) in virtually all patients. Higher doses have not demonstrated additional efficacy for pain reduction. The duration of treatment (3 months vs 6 months) shows a clearer dose-response relationship: 6-month courses achieve more complete lesion regression based on revised AFS scores compared to 3-month courses [8]. Add-back therapy with norethindrone acetate does not diminish pain relief efficacy but significantly reduces bone loss and vasomotor symptoms [8][16].

4.3 Central Precocious Puberty Dose Selection

In CPP, the 3.75 mg monthly dose provides adequate LH suppression in approximately 90% of children. The 11.25 mg 3-monthly formulation achieves suppression in 97.7%, likely due to more consistent plasma levels eliminating the late-interval troughs seen with monthly dosing [7]. Higher doses (beyond 11.25 mg per 12 weeks) have not been systematically studied in CPP.

4.4 IVF Trigger Dose-Response

For GnRH agonist triggering in IVF, doses of 0.1-0.2 mg SC produce an LH surge peaking at approximately 80-140 IU/L within 4-8 hours. The 0.2 mg dose produces a more reliable and robust LH surge than 0.1 mg, with no significant difference in OHSS risk (both approximately 0%). Doses above 0.2 mg have not shown additional benefit for oocyte maturation but may increase the already very low risk of luteal-phase hormone excess [9][10].

5. Researched Applications

Advanced Prostate Cancer (Strong Evidence -- FDA Approved)

Triptorelin depot is FDA-approved for the palliative treatment of advanced prostate cancer, achieving androgen deprivation through medical castration [1][15]. In the pivotal Phase 3 trial, triptorelin 3.75 mg monthly achieved castrate testosterone in 97% of patients by day 29, maintained in 93% through 9 months of treatment. PSA declined by more than 90% in the majority of patients [1].

A head-to-head noninferiority trial comparing triptorelin 3.75 mg monthly to leuprolide 7.5 mg monthly in 284 men with advanced prostate cancer demonstrated comparable efficacy: castration rates of 95.5% for triptorelin versus 96.4% for leuprolide, with no significant differences in safety profiles [3]. A systematic review by Bolton and Lynch (2018) confirmed that all GnRH agonists are comparably effective for testosterone suppression [5].

The 6-month depot (22.5 mg) was approved based on a trial showing 96.7% castration rate by day 29 with 97.4% maintenance through 48 weeks, offering improved convenience [4].

Endometriosis (Strong Evidence -- Approved in Europe)

Triptorelin 3.75 mg monthly for 6 months creates a hypoestrogenic state that induces atrophy of endometrial implants [8]. Randomized trials comparing triptorelin to danazol demonstrated equivalent pain relief (dysmenorrhea, dyspareunia, pelvic pain) with a superior side effect profile -- triptorelin avoids the androgenic effects (acne, hirsutism, voice deepening) associated with danazol [8]. As with leuprolide, add-back therapy with norethindrone acetate (5 mg daily) is recommended to mitigate bone loss and vasomotor symptoms during treatment beyond 6 months [1][16].

Central Precocious Puberty (Strong Evidence -- Approved in Europe)

Triptorelin is widely used for the treatment of central precocious puberty, particularly the 11.25 mg sustained-release formulation administered every 12 weeks [6][7]. In a Phase 3 study of 44 children, the 11.25 mg formulation effectively suppressed LH to prepubertal levels in 97.7%, with appropriate slowing of growth velocity and bone age advancement to preserve adult height potential [7].

IVF Trigger: The GnRH Agonist Alternative to hCG

One of triptorelin's most important roles is as a GnRH agonist trigger for final oocyte maturation in IVF antagonist protocols [9][10]. When a single dose of triptorelin (0.1-0.2 mg SC) is administered to patients who have been suppressed with a GnRH antagonist (cetrorelix or ganirelix), the acute flare effect induces an endogenous LH/FSH surge that triggers oocyte maturation. Key advantages over hCG triggering include [9][10]:

• Virtual elimination of OHSS. The endogenous gonadotropin surge is self-limiting (24-36 hours), unlike the sustained luteotrophic effect of hCG (half-life ~33 hours). OHSS rates drop from 5-10% (hCG) to approximately 0% (GnRH agonist trigger) [9].
• More physiological. The dual LH and FSH surge mirrors the natural midcycle gonadotropin surge.
• Safe in high responders. Particularly valuable in patients at high OHSS risk (polycystic ovary syndrome, high antral follicle counts, elevated estradiol).

However, GnRH agonist triggering results in inadequate corpus luteum function due to the brief gonadotropin surge, necessitating intensive luteal phase support or a "freeze-all" strategy with subsequent frozen embryo transfer [9][10].

Uterine Fibroids (Moderate Evidence -- Approved in Europe)

Preoperative triptorelin treatment for 3-6 months reduces fibroid volume by 45-55%, corrects iron-deficiency anemia, and reduces intraoperative blood loss, facilitating less invasive surgical approaches [1].

6. Clinical Evidence Summary

7. Comparative Effectiveness

7.1 Triptorelin vs Leuprolide

The most robust comparative data come from the Heyns et al. (2003) Phase 3 noninferiority RCT in 284 men with advanced prostate cancer [3]. Triptorelin 3.75 mg monthly and leuprolide 7.5 mg monthly demonstrated statistically indistinguishable castration rates (95.5% vs 96.4%), time to castration (median 22 days vs 21 days), PSA decline (more than 90% in both), and adverse event profiles. The noninferiority margin was met with high confidence [3].

Practical differences between the two agents include:

• Depot options: Leuprolide offers a broader range (1, 3, 4, 6 months plus daily SC), while triptorelin provides 1, 3, and 6 months
• Route: Triptorelin is exclusively IM; leuprolide is available as both IM (Lupron Depot) and SC (Eligard)
• Self-administration: Leuprolide SC (Eligard) can be self-administered; triptorelin requires clinic visits for IM injection
• Cost and availability: Triptorelin is typically less expensive and more widely used in Europe, while leuprolide dominates the US market due to earlier FDA approval and broader indications [5][17]

7.2 Triptorelin vs Goserelin

No large head-to-head RCTs directly compare triptorelin to goserelin. Indirect comparisons via network meta-analysis and the Bolton systematic review (2018) suggest equivalent castration rates (95-97% for triptorelin vs 95-98% for goserelin), comparable PSA suppression, and similar cardiovascular risk profiles [5]. Goserelin's subcutaneous implant delivery is generally considered more convenient than triptorelin's IM injection, but triptorelin offers a 6-month depot option not available with goserelin (limited to 1 and 3 months) [5][17].

7.3 Triptorelin vs Degarelix (GnRH Antagonist)

Degarelix, a GnRH antagonist, offers a fundamentally different pharmacological approach -- immediate competitive receptor blockade without the initial flare phase [16][18]:

| Feature | Triptorelin (Agonist) | Degarelix (Antagonist) | |---------|-----------------------|------------------------| | Onset of castration | 2-4 weeks (after flare) | 1-3 days (no flare) | | Testosterone flare | Yes (Days 1-7) | No | | Need for antiandrogen flare protection | Yes | No | | Depot options | 1, 3, 6 months | Monthly only (240/80 mg) | | Injection site reactions | 5-10% (IM) | 40% (SC, large volume) | | PSA progression | Similar long-term | Faster initial PSA decline | | Cardiovascular risk | Standard ADT risk (HR ~1.4) | Possibly lower MACE risk (HERO trial data for relugolix) | | Long-acting formulations | Available (3, 6 months) | None (monthly only) |

In the HERO trial, the oral GnRH antagonist relugolix demonstrated a 54% reduction in MACE compared to leuprolide, suggesting that the GnRH antagonist class may carry lower cardiovascular risk [18]. Whether this applies to degarelix versus triptorelin remains unconfirmed in dedicated comparative trials. The absence of a testosterone flare with degarelix is clinically meaningful in patients with impending spinal cord compression or severe obstructive symptoms [16][18].

7.4 For Endometriosis: Triptorelin vs Other GnRH Agonists

All GnRH agonists demonstrate equivalent efficacy for endometriosis pain relief when compared in trials [5][8]. The choice between triptorelin, leuprolide, and goserelin for endometriosis is driven by:

• Regional availability (triptorelin dominant in Europe, leuprolide in US)
• Patient preference for injection route and frequency
• Insurance and cost considerations

Nafarelin (intranasal) offers a needle-free alternative but requires twice-daily dosing with lower bioavailability and more variable absorption [5].

8. Comparison with Other GnRH Agonists

| Feature | Triptorelin (Trelstar/Decapeptyl) | Leuprolide (Lupron/Eligard) | Goserelin (Zoladex) | |---------|----------------------------------|---------------------------|-------------------| | Modification | D-Trp6 only | D-Leu6 + Pro9-NHEt | D-Ser(tBu)6 + AzGly10 | | Potency vs GnRH | ~100x | ~15-20x | ~100x | | Route | Intramuscular | IM or subcutaneous | Subcutaneous implant | | Depot options | 1, 3, 6 months | 1, 3, 4, 6 months | 1, 3 months | | US approval | Prostate cancer only | Broadest (prostate, endo, fibroids, CPP) | Prostate, breast, endo | | European approval | Broadest (prostate, endo, fibroids, CPP, IVF) | Similar to US | Similar to US | | Castration rate | 95-97% | 93-96% | 95-98% | | Generic available | Yes (limited) | Yes (limited) | No |

The systematic review by Bolton and Lynch (2018) concluded that all GnRH agonists are comparably effective for testosterone suppression, with the choice between agents driven primarily by depot duration preferences, injection route, and regional availability [5].

9. Dosing in Research

Advanced prostate cancer. Trelstar 3.75 mg IM every 4 weeks; or 11.25 mg IM every 12 weeks; or 22.5 mg IM every 24 weeks. Antiandrogen co-therapy (bicalutamide 50 mg daily) is recommended starting 1-2 weeks before the first injection and continuing for 2-4 weeks to prevent clinical flare [15].

Endometriosis. Decapeptyl 3.75 mg IM every 4 weeks for up to 6 months. Add-back therapy with norethindrone acetate 5 mg daily is recommended beyond 3 months to mitigate bone loss [1][8].

Central precocious puberty. Decapeptyl 3.75 mg IM every 4 weeks, or 11.25 mg IM every 12 weeks. Treatment continues until appropriate pubertal age [6][7].

IVF trigger. Triptorelin 0.1-0.2 mg SC as a single dose when lead follicles reach 17-18 mm in GnRH antagonist protocols. Requires intensive luteal phase support or freeze-all strategy [9][10].

10. Safety and Side Effects

The adverse effect profile of triptorelin is a GnRH agonist class effect, shared with leuprolide and goserelin [1][5][15][19]:

Vasomotor symptoms. Hot flashes in 50-75% of patients (the most common adverse effect). Result from sex steroid withdrawal affecting hypothalamic thermoregulation [15].

Testosterone/estradiol flare. Transient hormonal surge during the first 1-2 weeks. In prostate cancer, may worsen bone pain, urinary obstruction, or spinal cord compression. Managed with antiandrogen co-therapy [14][15].

Bone mineral density loss. Accelerated bone resorption from sex steroid deprivation. In men, 2-3% annual BMD loss at the lumbar spine. DEXA monitoring and bisphosphonate/denosumab therapy may be required for long-term ADT [1][15].

Cardiovascular and metabolic risk. Class effect of GnRH agonist ADT: increased diabetes (HR ~1.4), coronary heart disease, and metabolic syndrome [5][19].

Sexual dysfunction. Loss of libido, erectile dysfunction in men; vaginal dryness in women [15].

Musculoskeletal. Arthralgia, myalgia, skeletal pain (particularly early treatment) [15].

Injection site reactions. Pain, erythema, and induration at the IM injection site in 5-10% [15].

Rare but serious. Pituitary apoplexy (extremely rare), anaphylaxis, QTc prolongation (class labeling) [15].

11. Enhanced Safety Considerations

11.1 Cardiovascular Risk Mitigation

GnRH agonist therapy including triptorelin increases cardiovascular and metabolic risk through androgen deprivation-mediated changes in body composition, lipid metabolism, insulin sensitivity, and vascular function [5][19]. Evidence-based mitigation strategies include:

• Baseline cardiovascular assessment prior to initiating ADT, including fasting glucose/HbA1c, lipid panel, blood pressure, and cardiac history review. Patients with pre-existing cardiovascular disease or diabetes require closer monitoring [19].
• Metabolic monitoring every 3-6 months: fasting glucose, HbA1c, lipid panel, weight, and waist circumference. Metabolic syndrome develops in approximately 50% of men receiving long-term ADT [19].
• Exercise prescription. Supervised resistance and aerobic exercise programs have been shown to attenuate lean mass loss, fat gain, and insulin resistance during ADT. Multiple RCTs support exercise as a standard component of ADT-related care [19].
• Consideration of GnRH antagonist alternatives. The HERO trial demonstrated a 54% lower rate of MACE with relugolix compared to leuprolide, suggesting that patients with significant cardiovascular risk may benefit from a GnRH antagonist approach [18]. This remains an active area of investigation.

11.2 Bone Health Management

Long-term triptorelin therapy causes clinically significant bone loss that may lead to osteoporosis and fragility fractures, particularly in men receiving ADT for prostate cancer [1][15]:

• DEXA monitoring at baseline and annually during treatment lasting more than 6 months
• Calcium (1200 mg daily) and vitamin D (800-1000 IU daily) supplementation for all patients on ADT
• Bisphosphonate or denosumab therapy for patients with T-score at or below -2.5 or a history of fragility fracture. Denosumab 60 mg SC every 6 months has demonstrated a 62% reduction in vertebral fracture risk in men on ADT
• Fall prevention assessment including vision, balance, and home safety evaluation in older patients

11.3 Flare Prevention

The initial testosterone surge during the first 1-2 weeks of treatment can cause clinically significant flare in patients with high-volume metastatic disease:

• Antiandrogen coverage with bicalutamide 50 mg daily (or flutamide 250 mg TID) starting 1-2 weeks before and continuing 2-4 weeks after the first triptorelin injection [14][15]
• Monitor for spinal cord compression symptoms in patients with known vertebral metastases
• Consider degarelix as an alternative first injection in patients with symptomatic disease at high flare risk (impending cord compression, severe bladder outlet obstruction), followed by triptorelin depot for maintenance if desired [16]

11.4 Monitoring for Long-Term ADT

| Parameter | Frequency | Action Threshold | |-----------|-----------|-----------------| | Testosterone | Every 3-6 months | Confirm at or below 50 ng/dL (target at or below 20 ng/dL) | | PSA | Every 3-6 months | Rising PSA prompts evaluation for castration resistance | | DEXA | Annual | T-score at or below -2.5: initiate bone-protective therapy | | Fasting glucose/HbA1c | Every 6 months | HbA1c 6.5% or above: diabetes management | | Lipid panel | Every 6 months | Treat per cardiovascular guidelines | | CBC | Annual | Monitor for anemia (common with ADT) | | Body weight/composition | Every 3-6 months | Exercise and dietary counseling |

11.5 Fertility Preservation

Triptorelin suppresses spermatogenesis, and azoospermia typically develops within 2-3 months of initiating therapy. While testosterone and fertility generally recover within 3-6 months of discontinuation, recovery is not guaranteed, particularly after prolonged ADT (more than 2 years). Sperm banking should be offered to all men of reproductive age before initiating triptorelin therapy [15].

In women receiving triptorelin for endometriosis, ovarian function and fertility typically recover within 1-3 months of treatment cessation. The use of add-back therapy does not impair fertility recovery [8].

12. Regulatory Status

United States (FDA). Trelstar (triptorelin pamoate for injectable suspension) was approved in 2000 for palliative treatment of advanced prostate cancer. Available as 3.75 mg (monthly), 11.25 mg (3-month), and 22.5 mg (6-month) depot formulations. Currently marketed by Verity Pharmaceuticals (under license from Ipsen/Debiopharm) [15].

European Union (EMA). Decapeptyl (triptorelin acetate and pamoate) is approved for advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and assisted reproduction. Widely used across Europe, with the broadest indication set of any GnRH agonist.

Development history. Triptorelin was synthesized and characterized by Andrew Schally and colleagues at Tulane University. Developed commercially by Ipsen/Debiopharm (Decapeptyl) and Verity/Allergan (Trelstar).

13. Related Peptides

See also: Leuprolide (Lupron/Eligard), Goserelin (Zoladex), Gonadorelin (GnRH), Nafarelin (Synarel), Cetrorelix (Cetrotide), Degarelix (Firmagon)

14. References

1. [1] Debruyne FM, Gouveia MC. (2006). Triptorelin -- A Review of the Clinical Experience. Expert Opin Pharmacother. DOI PubMed
2. [2] Crawford ED, Eisenberger MA, McLeod DG, et al. (1989). A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma. N Engl J Med. DOI PubMed
3. [3] Heyns CF, Simonin MP, Grosgurin P, et al. (2003). Comparative Efficacy of Triptorelin Pamoate and Leuprolide Acetate in Men with Advanced Prostate Cancer. BJU Int. DOI PubMed
4. [4] Lundstrom EA, Rosen A, Guthrie GP, et al. (2010). Triptorelin 6-Month Formulation in the Management of Patients with Locally Advanced and Metastatic Prostate Cancer. Clin Drug Investig. DOI PubMed
5. [5] Bolton EM, Lynch TH. (2018). Are All Gonadotrophin-Releasing Hormone Agonists Equivalent for the Treatment of Prostate Cancer? A Systematic Review. BJU Int. DOI PubMed
6. [6] Carel JC, Eugster EA, Rogol A, et al. (2009). Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children. Pediatrics. DOI PubMed
7. [7] Caron P, Bex M, Cullen DR, et al. (2007). One-Year Sustained Efficacy of Triptorelin Pamoate 11.25 mg for Central Precocious Puberty. J Pediatr Endocrinol Metab. DOI PubMed
8. [8] Bergqvist A, Bergh T, Hogstrom L, et al. (1993). Effects of Triptorelin versus Danazol in the Treatment of Endometriosis. Fertil Steril. DOI PubMed
9. [9] Humaidan P, Kol S, Papanikolaou EG. (2011). GnRH Agonist for Triggering of Final Oocyte Maturation -- Time for a Change of Practice?. Hum Reprod Update. DOI PubMed
10. [10] Youssef MA, van der Veen F, Al-Inany HG, et al. (2014). Gonadotropin-Releasing Hormone Agonist versus HCG for Oocyte Triggering in Antagonist-Assisted Reproductive Technology. Cochrane Database Syst Rev. DOI PubMed
11. [11] Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. (2004). Gonadotropin-Releasing Hormone Receptors. Endocr Rev. DOI PubMed
12. [12] Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. (1978). Hypophysial Responses to Continuous and Intermittent Delivery of Hypothalamic Gonadotropin-Releasing Hormone. Science. DOI PubMed
13. [13] Conn PM, Crowley WF Jr. (1994). Gonadotropin-Releasing Hormone and Its Analogs. Annu Rev Med. DOI PubMed
14. [14] Labrie F, Belanger A, Luu-The V, et al. (2005). Gonadotropin-Releasing Hormone Agonists in the Treatment of Prostate Cancer. Endocr Rev. DOI PubMed
15. [15] Trelstar Prescribing Information (2024). Trelstar (Triptorelin Pamoate): Full Prescribing Information. Verity Pharmaceuticals / FDA. PubMed
16. [16] Engel JB, Schally AV. (2007). Drug Insight -- Clinical Use of Agonists and Antagonists of Luteinizing-Hormone-Releasing Hormone. Nat Clin Pract Endocrinol Metab. DOI PubMed
17. [17] Meani D, Solaric M, Visapaa H, et al. (2018). Practical Differences between Luteinizing Hormone-Releasing Hormone Agonists in Prostate Cancer. Ther Adv Urol. DOI PubMed
18. [18] Shore ND, Saad F, Cookson MS, et al. (2020). Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer (HERO). N Engl J Med. DOI PubMed
19. [19] Gupta D, Lee Chuy K, Yang JC, et al. (2021). Cardiovascular Toxicity of Androgen Deprivation Therapy. Curr Treat Options Oncol. DOI PubMed
20. [20] Humaidan P, Bredkjaer HE, Bungum L, et al. (2005). GnRH Agonist (Buserelin) or HCG for Ovulation Induction in GnRH Antagonist IVF/ICSI Cycles -- A Prospective Randomized Study. Hum Reprod. DOI PubMed